01941nas a2200445   4500000000100000008004100001260001300042653001500055653001000070653002100080653001600101653002500117653001000142653002100152653002500173653001100198653001100209653001400220653001000234653001200244653000900256653001600265653001500281653002400296653001700320653002100337653001700358100001400375700001200389700001400401700001200415700001200427700001200439245010600451856004100557300001000598490000700608520086600615022001401481       1993                            d  c1993 Dec10aAdolescent10aAdult10aAge Distribution10aBCG Vaccine10aCase-Control Studies10aChild10aChild, Preschool10aConfidence Intervals10aFemale10aHumans10aIncidence10aKenya10aleprosy10aMale10aMiddle Aged10aOdds Ratio10aRegression Analysis10aRisk Factors10aSex Distribution10aTuberculosis1 aOrege P A1 aFine PE1 aLucas S B1 aObura M1 aOkelo C1 aOkuku P00aCase-control study of BCG vaccination as a risk factor for leprosy and tuberculosis in western Kenya.  uhttp://ila.ilsl.br/pdfs/v61n4a02.pdf  a542-90 v613 a<p>A case-control study was carried out in western Kenya to measure the protection imparted by BCG against leprosy and tuberculosis. The study involved 69 newly diagnosed leprosy cases, 238 age-, sex- and neighborhood-matched controls, and 144 newly diagnosed, sputum-smear-positive tuberculosis cases along with 432 age-, sex- and neighborhood-matched controls. Information on BCG vaccination history was inferred from scars. Using matched analysis, the protection imparted by BCG against leprosy was estimated to be 81% [95% confidence interval (CI) = 67-90] with no apparent difference in protection against paucibacillary [vaccine efficacy (VE) = 83%, 95% CI = 58-92] and multibacillary leprosy (VE = 76%; 95% CI = 30-91). The effectiveness against tuberculosis was appreciably lower (VE = 22%) and was not statistically significant (95% CI = -20-51).</p>
  a0148-916X